Our findings identify astrocytic LAG3 as a critical mediator linking sleep deprivation to glymphatic dysfunction and PD progression. Targeting LAG3 may represent a promising, albeit early-stage, therapeutic strategy to mitigate α-syn pathology in PD patients with sleep disorders.
Sun et al. (Wed,) studied this question.